Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Cash from Financing Activities: 2017-2025

Historic Cash from Financing Activities for Arcus Biosciences (RCUS) over the last 9 years, with Sep 2025 value amounting to $8.0 million.

  • Arcus Biosciences' Cash from Financing Activities fell 83.33% to $8.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $200.0 million, marking a year-over-year decrease of 29.08%. This contributed to the annual value of $277.0 million for FY2024, which is 739.39% up from last year.
  • According to the latest figures from Q3 2025, Arcus Biosciences' Cash from Financing Activities is $8.0 million, which was down 84.62% from $52.0 million recorded in Q2 2025.
  • Over the past 5 years, Arcus Biosciences' Cash from Financing Activities peaked at $229.0 million during Q1 2024, and registered a low of -$2.0 million during Q4 2024.
  • In the last 3 years, Arcus Biosciences' Cash from Financing Activities had a median value of $8.0 million in 2025 and averaged $46.5 million.
  • Per our database at Business Quant, Arcus Biosciences' Cash from Financing Activities skyrocketed by 36,313.11% in 2021 and then tumbled by 166.67% in 2024.
  • Arcus Biosciences' Cash from Financing Activities (Quarterly) stood at $11.3 million in 2021, then declined by 2.92% to $11.0 million in 2022, then tumbled by 72.73% to $3.0 million in 2023, then crashed by 166.67% to -$2.0 million in 2024, then crashed by 83.33% to $8.0 million in 2025.
  • Its Cash from Financing Activities was $8.0 million in Q3 2025, compared to $52.0 million in Q2 2025 and $142.0 million in Q1 2025.